Ketamine One Appoints Loreto Grimaldi to Board of Directors
Ketamine One Capital Limited has appointed Loreto Grimaldi to its Board of Directors, enhancing the company’s governance with over 25 years of experience in corporate law and governance. Grimaldi's background in healthcare and technology positions him as a valuable asset as the company aims to lead in mental health treatments. Ketamine One currently operates 15 clinics across North America and aims to expand further, having recently added KGK Science as its contract research division, positioning itself for growth in the fragmented mental health industry.
- Appointment of Loreto Grimaldi to the Board of Directors brings extensive experience and insights.
- Recent addition of KGK Science enhances clinical research capabilities.
- None.
Insights
Analyzing...
Accomplished Executive and Director Brings Experience From a Wide Range of Industries Across North America
VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has recently appointed Loreto Grimaldi to its Board of Directors. Mr. Grimaldi brings over 25 years of corporate, transactional and governance experience to Ketamine One. He is licensed to practice law in Ontario and New York State, and maintains active memberships in the American Bar Association, the Association of Corporate Counsel, the National Association of Corporate Directors, and the Institute of Corporate Directors. Mr. Grimaldi is expected to provide invaluable insights to the Company as it grows, due to his previous time spent in the healthcare and technology industries, among others.
“On behalf of the Company, I extend a warm welcome Loreto as the newest member of Ketamine One’s Board of Directors,” said Rob Meister, Chief Executive Officer of Ketamine One. “Given the Company’s focus on emerging areas of mental health, adding a forward-thinking professional with a proven track record of business and legal excellence is a great fit,” added Mr. Meister.
Mr. Grimaldi currently serves as Chair of the HR and Compensation Committee for Aleafia Health, with whom Ketamine One recently completed a significant transaction to expand the Company’s clinical network. Loreto is also the co-founder of Untether Capital Inc. dba Fleets Coffee, which is a disruptive food technology platform. At the Schulich School of Business, he is an adjunct professor where he teaches Business Law to BBA and MBA students.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry. The recent addition of KGK Science Inc. as the Company’s contract research division also places the company at the forefront of premium clinical research based on its 23-year history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
"Robert Meister"
Robert Meister, CEO and Director
For further information, please contact:
Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and future prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
FAQ
Who is Loreto Grimaldi and what is his role at Ketamine One?
What does Ketamine One focus on in the healthcare sector?
How many clinics does Ketamine One currently operate?
What recent strategic move has Ketamine One made regarding clinical research?
